Kura Oncology Reports $18.3 Million Revenue in Q1 2026, Net Loss Increases to $73.3 Million

Kura Oncology, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $18.3 million, a significant increase from $14.1 million in the same period of 2025. This growth was primarily driven by the introduction of product revenue from KOMZIFTI, which generated $5.8 million in its first full quarter of sales following FDA approval in November 2025. Collaboration revenue, however, saw a decline, dropping to $12.5 million from $14.1 million year-over-year, attributed to changes in the timing and nature of services performed under the Kyowa License Agreement.

The company experienced a net loss of $73.3 million for the quarter, compared to a loss of $57.4 million in the prior year. This increase in loss was largely due to higher operating expenses, which rose to $97.1 million from $78.8 million, reflecting increased costs associated with research and development, particularly for ziftomenib-related trials, and higher selling, general, and administrative expenses. Research and development expenses alone increased to $65.3 million from $56.0 million, driven by ongoing clinical trials and personnel costs.

Kura's balance sheet as of March 31, 2026, showed total assets of $652.6 million, down from $738.4 million at the end of 2025. The decrease was primarily due to a reduction in cash and cash equivalents, which fell to $39.1 million from $149.1 million, while short-term investments increased slightly to $541.7 million. Total liabilities decreased to $544.7 million from $564.2 million, with current liabilities also declining, reflecting improved management of accounts payable and accrued expenses.

Strategically, Kura has made significant advancements in its product pipeline, particularly with KOMZIFTI, which is now included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as a recommended treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The company is also actively pursuing additional clinical trials for ziftomenib in various settings, including combinations with standard therapies for AML. As of March 31, 2026, Kura had cash, cash equivalents, and short-term investments totaling $580.8 million, which management believes will be sufficient to fund operations into the fourth quarter of 2027, although they anticipate needing additional financing to support ongoing and future development activities.